COVID-19 and the cardiovascular system

Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antiviral Agents / adverse effects
  • Betacoronavirus
  • Cardiotoxicity
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / virology
  • Cardiovascular System / pathology
  • Cardiovascular System / virology*
  • Coronavirus Infections / complications*
  • Coronavirus Infections / physiopathology*
  • Heart / virology
  • Heart Diseases / virology*
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Myocardium / pathology
  • Pandemics
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / physiopathology*
  • Receptors, Virus / antagonists & inhibitors
  • Receptors, Virus / metabolism

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antiviral Agents
  • Receptors, Virus
  • Peptidyl-Dipeptidase A
  • angiotensin converting enzyme 2

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2